Tolerance in the Post-Vioxx Era
This article was originally published in RPM Report
Executive Summary
The phrase post "post-Vioxx environment" is the cliché du jour in pharma: the simple way to explain any setback in drug development. The question is how much time will Wall Street allow a company while it works to clear the regulatory hurdle. Palatin Technologies' NeutroSpec is a good case example.
You may also be interested in...
Pazdur’s Big Moment: ‘Project Odyssey’ Webinar Gives Oncology Chief External Buy-In On His Ideas To Revamp ODAC
OCE Director Richard Pazdur is known for cultivating 'Pazdur moments' during advisory committees when he feels the conversation has gone off track. A recent webinar with ODAC members created a perfect opportunity to promote his agenda.
Another Chance For VALID? Negative Reaction To FDA’s LDT Proposal May Reopen Legislative Talks
All of the witnesses testifying to a House E&C Committee hearing said they preferred the flexibility and targeted enforcement of the VALID Act to FDA’s proposed rule. Will Congress finally be spurred to act?
US FDA Advisory Panels May Look Different Across Centers, Despite Efforts To Standardize Process
As FDA is readying to go back to in-person advisory committee meetings this fall, the centers have different ideas about how to use their expert panels.